These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 37553420)

  • 1. Immune checkpoint inhibitor-associated adrenal insufficiency in Chinese cancer patients: a retrospective analysis.
    Cai Q; Wu W; Li X; Xu Q; Zhao L; Lv Q
    J Cancer Res Clin Oncol; 2023 Nov; 149(15):14113-14123. PubMed ID: 37553420
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical characteristics and treatment efficacy of immune checkpoint inhibitors (ICIs) in patients with ICIs-induced Adrenal insufficiency.
    Xiang J; Liu X; Hao Y; Zhu Y; Wu M; Lou J; Wang Y; Xu C; Xie Y; Huang J
    Transl Oncol; 2023 Dec; 38():101787. PubMed ID: 37729740
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical characteristics and outcomes of patients with primary liver cancer and immune checkpoint inhibitor-associated adrenal insufficiency: A retrospective cohort study.
    Cai Q; Wu W; Li R; Li X; Xu Q; Zhao L; Lv Q
    Int Immunopharmacol; 2024 Jan; 127():111337. PubMed ID: 38064811
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immune Checkpoint Inhibitor-Associated Primary Adrenal Insufficiency: WHO VigiBase Report Analysis.
    Grouthier V; Lebrun-Vignes B; Moey M; Johnson DB; Moslehi JJ; Salem JE; Bachelot A
    Oncologist; 2020 Aug; 25(8):696-701. PubMed ID: 32390168
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immune checkpoint inhibitors and adrenal insufficiency: a large-sample case series study.
    Cui K; Wang Z; Zhang Q; Zhang X
    Ann Transl Med; 2022 Mar; 10(5):251. PubMed ID: 35402601
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Real-World Clinical and Economic Outcomes in Selected Immune-Related Adverse Events Among Patients with Cancer Receiving Immune Checkpoint Inhibitors.
    Zheng Y; Kim R; Yu T; Gayle JA; Wassel CL; Dreyfus J; Phatak H; George S
    Oncologist; 2021 Nov; 26(11):e2002-e2012. PubMed ID: 34327774
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of outcomes in patients with advanced genitourinary malignancies treated with immune checkpoint inhibitors.
    Ma VT; Su CT; Hu M; Taylor JMG; Daignault-Newton S; Kellezi O; Dahl MN; Shah MA; Erickson S; Lora J; Hamasha R; Ali A; Yancey S; Kiros L; Balicki HM; Winfield DC; Green MD; Alva AS
    Urol Oncol; 2021 Jul; 39(7):437.e1-437.e9. PubMed ID: 33495117
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Primary adrenal insufficiency induced by immune checkpoint inhibitors: biological, clinical, and radiological aspects.
    Martella S; Lucas M; Porcu M; Perra L; Denaro N; Pretta A; Deias G; Willard-Gallo K; Parra HS; Saba L; Scartozzi M; Wekking D; Kok M; Aiello MM; Solinas C
    Semin Oncol; 2023 Dec; 50(6):144-148. PubMed ID: 38151399
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immune checkpoint inhibitor combination therapies very frequently induce secondary adrenal insufficiency.
    Manaka K; Sato J; Takeuchi M; Watanabe K; Kage H; Kawai T; Sato Y; Miyagawa T; Yamada D; Kume H; Sato S; Nagase T; Iiri T; Nangaku M; Makita N
    Sci Rep; 2021 Jun; 11(1):11617. PubMed ID: 34078988
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Endocrine toxicity of immune checkpoint inhibitors: a real-world study leveraging US Food and Drug Administration adverse events reporting system.
    Zhai Y; Ye X; Hu F; Xu J; Guo X; Zhuang Y; He J
    J Immunother Cancer; 2019 Nov; 7(1):286. PubMed ID: 31694698
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Eosinophil counts can be a predictive marker of immune checkpoint inhibitor-induced secondary adrenal insufficiency: a retrospective cohort study.
    Takayasu S; Mizushiri S; Watanuki Y; Yamagata S; Usutani M; Nakada Y; Asari Y; Murasawa S; Kageyama K; Daimon M
    Sci Rep; 2022 Jan; 12(1):1294. PubMed ID: 35079086
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Endocrine immune-related adverse events in patients with metastatic renal and urothelial cancer treated with immune checkpoint-inhibitors.
    Oppolzer IA; Riester J; Büttner R; Burger M; Schnabel MJ
    Int Urol Nephrol; 2023 Aug; 55(8):1943-1949. PubMed ID: 37271776
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rethinking the management of immune checkpoint inhibitor-related adrenal insufficiency in cancer patients during the COVID-19 pandemic.
    Yuen KCJ; Mortensen MJ; Azadi A; Fonkem E; Findling JW
    Endocrinol Diabetes Metab; 2021 Jul; 4(3):e00246. PubMed ID: 34268454
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hypophysitis and Secondary Adrenal Insufficiency From Immune Checkpoint Inhibitors: Diagnostic Challenges and Link With Survival.
    Johnson J; Goldner W; Abdallah D; Qiu F; Ganti AK; Kotwal A
    J Natl Compr Canc Netw; 2023 Feb; 21(3):281-287. PubMed ID: 36828029
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical characteristics of gastrointestinal immune-related adverse events of immune checkpoint inhibitors and their association with survival.
    Yamada K; Sawada T; Nakamura M; Yamamura T; Maeda K; Ishikawa E; Iida T; Mizutani Y; Kakushima N; Ishikawa T; Furukawa K; Ohno E; Honda T; Kawashima H; Ishigami M; Furune S; Hase T; Yokota K; Maeda O; Hashimoto N; Akiyama M; Ando Y; Fujishiro M
    World J Gastroenterol; 2021 Nov; 27(41):7190-7206. PubMed ID: 34887637
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immune checkpoint inhibitors in first-line therapies of metastatic or early triple-negative breast cancer: a systematic review and network meta-analysis.
    Liang X; Chen X; Li H; Li Y
    Front Endocrinol (Lausanne); 2023; 14():1137464. PubMed ID: 37229447
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immune Checkpoint Inhibitors in the Treatment of Patients With Cancer and Preexisting Psoriasis: A Systematic Review and Meta-Analysis of Observational Studies.
    Yu Y; Zhou Y; Zhang X; Tan K; Zheng J; Li J; Cui H
    Front Oncol; 2022; 12():934093. PubMed ID: 35912183
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Persistent immune-related adverse events after cessation of checkpoint inhibitor therapy: Prevalence and impact on patients' health-related quality of life.
    Schulz TU; Zierold S; Sachse MM; Pesch G; Tomsitz D; Schilbach K; Kähler KC; French LE; Heinzerling L
    Eur J Cancer; 2022 Nov; 176():88-99. PubMed ID: 36198246
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ocular Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors in Lung Cancer.
    Zhou L; Wei X
    Front Immunol; 2021; 12():701951. PubMed ID: 34504488
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ophthalmic immune-related adverse events associated with immune checkpoint inhibitors.
    Gan L; Chen H; Liu X; Zhang L
    Front Immunol; 2023; 14():1130238. PubMed ID: 37033964
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.